🔥🐔 BizChicken 🐔🔥

Companies Similar to Genprex, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

CARGO Therapeutics, Inc. Common Stock

CARGO Therapeutics, Inc. Common Stock logo
Market Cap: Medium
Employees: Low

CRG-022

CARGO Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing chimeric antigen receptor (CAR) T-cell therapies for cancer patients. Their lead program, CRG-022, targets resistance mechanisms in B-cell malignancies.

Tags: B-cell Malignancies, Biotechnology, CAR T-cell Therapies, Cancer Treatment, Clinical-stage

Symbol: CRGX

Recent Price: $13.76

Industry: Biotechnology

CEO: Ms. Gina Chapman

Sector: Healthcare

Employees: 150

Address: 1900 Alameda De Las Pulgas, San Mateo, null 94403

Phone: 650-379-6143

Leadership

  • Gina Chapman, President and Chief Executive Officer
  • Anup Radhakrishnan, Chief Financial Officer/Chief Business Officer
  • Ginna Laport, MD, Chief Medical Officer
  • Shishir Gadam, PhD, Chief Technical Officer
  • Michael Ports, PhD, Chief Scientific Officer
  • Kari Leetch, Chief People Officer
  • Halley Gilbert, JD, Chief Legal Officer
  • Bethany Rogers, SVP, Product Strategy and Commercialization
  • Faisal Shawwa, SVP, Finance
  • Tonia J. Buchholz, PhD, Head of Clinical Science
  • Kanika Chawla, PhD, Head of Process Sciences
  • Sandra Chen, Head of Clinical Quality and Risk Management
  • Michelle Gray, Head of Clinical Operations
  • Adam Haskett, Head of External Manufacturing
  • David Hoffman, JD, Head of Intellectual Property & Transactions
  • Anissa Irwin, Head of Quality Assurance and Systems
  • Brett Masterson, Head of Marketing
  • Rob McCombie, Head of CMC Regulatory
  • Frank McDonald, Head of Clinical Data Management
  • Priya Parameswaran, Head of Corporate Strategy and Business Operations
  • Shabnum Patel, PHD, Head of MSAT
  • Mary Rodley, Head of CMC Strategy and Operations
  • Abhijeet Sarvaiya, Head of Statistical Programming
  • Brian Schoelkopf, Head of FP&A
  • Christophe Suchet, Head of IT
  • Beth Vasievich, PhD, Head of Commercial Planning and Operations
  • Jun Wang, Head of Procurement
  • John Orwin, Chairman of the Board
  • Abraham Bassan, Board Director
  • Kapil Dhingra, M.B.B.S, Board Director
  • Reid Huber, PHD, Board Director
  • David Lubner, Board Director
  • Krishnan Viswanadhan, Pharm.D, Board Director
  • Jane Pritchett Henderson, Board Director

Last updated: 2024-12-31

Genprex, Inc.

Genprex, Inc. logo
Market Cap: Lowest
Employees: Lowest

REQORSA (GPX-001)

Genprex, Inc. is a clinical-stage gene therapy company developing therapies for cancer and diabetes, with a lead product candidate REQORSA for lung cancer treatment.

Tags: biotechnology, cancer, diabetes, gene therapy, pharmaceuticals

Symbol: GNPX

Recent Price: $0.85

Industry: Biotechnology

CEO: Mr. Ryan M. Confer M.S.

Sector: Healthcare

Employees: 21

Address: 3300 Bee Cave Road, Austin, TX 78746

Phone: 877 774 4679

Leadership

  • Amy Patel, Quality Assurance Manager
  • Celina Laney, Senior Administrative Services Manager
  • Edith Padilla, Clinical Research Associate II
  • Gina Johnson, Quality Control Manager, Stability & Product Lifecycle Management
  • Greg Jancarik, MBA, CMA, CPA, Corporate Controller
  • Jackie Opiola, Senior Clinical Project Manager
  • John Ayres, Associate Vice President & Associate General Counsel
  • Kalyn Dabbs, Senior Manager of Communications and Marketing
  • Kate Combs, Vice President of Clinical Operations
  • Laura Tirado, Senior Manager, CMC Project Management
  • Olivia Stancil, Senior Clinical Trial Assistant
  • Pier-Anne Lachance, Director of Quality Control & Product Development
  • Sarah Nguyen, Senior Manager of Quality Assurance Operations
  • Jose A. Moreno Toscano, Board Chairman
  • Ryan M. Confer, MS, President, Chief Executive Officer, Chief Financial Officer
  • Brent Longnecker, Board Director
  • William Wilson, Jr., Board Director
  • James E. Rothman, PhD, Strategic Advisor to the Board of Directors

Last updated: 2024-12-31

Precigen, Inc.

Precigen, Inc. logo
Market Cap: Low
Employees: Low

gene and cellular therapies

Precigen, Inc. is focused on discovering and developing advanced gene and cellular therapies, disease-modifying therapeutics, and genetic engineering technologies for regenerative medicine and other applications.

Tags: biotechnology, cellular therapy, gene therapy, genetic engineering, regenerative medicine

Symbol: PGEN

Recent Price: $0.93

Industry: Biotechnology

CEO: Dr. Helen Sabzevari MPH, Ph.D.

Sector: Healthcare

Employees: 202

Address: 20374 Seneca Meadows Parkway, Germantown, MD 20876

Phone: 301 556 9900

Last updated: 2024-12-31

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: Highest

EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara, Inmazeb

Regeneron Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide, including treatments like EYLEA, Dupixent, Libtayo, and more.

Tags: biotechnology, diseases, healthcare, injections, medicines, pharmaceuticals, treatment

Symbol: REGN

Recent Price: $702.59

Industry: Biotechnology

CEO: Dr. Leonard S. Schleifer M.D., Ph.D.

Sector: Healthcare

Employees: 14165

Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707

Phone: 914 847 7000

Leadership

  • Leonard S. Schleifer, MD, PhD, Board co-Chair, President and Chief Executive Officer
  • George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer
  • Zoran Berkovic, Senior Vice President, Financial Planning and Analysis
  • Maya Bermingham, Senior Vice President, Public Policy and Government Affairs
  • Leonard Brooks, Senior Vice President, Treasurer
  • John Calabro, Senior Vice President, Internal Audit
  • Christina Chan, Senior Vice President, Corporate Affairs
  • Larry Coury, PhD, Senior Vice President, Associate General Counsel
  • Ryan Crowe, Senior Vice President, Investor Relations & Strategic Analysis
  • Matthew Everett, Senior Vice President, Global Procurement
  • Chris Fenimore, Senior Vice President, Finance and Chief Financial Officer
  • Rick Hall, Senior Vice President, Human Resources
  • Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit
  • Nouhad Husseini, Senior Vice President, Business Development
  • Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary
  • Melissa Lozner, Senior Vice President, Chief Compliance Officer
  • Marion McCourt, Executive Vice President, Commercial
  • Bob McCowan, Senior Vice President, IT and Chief Information Officer
  • Gonzalo Merino, PhD, Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel
  • Richard O’Neal, Senior Vice President, Market Access
  • Sally A. Paull, Executive Vice President, Human Resources
  • Smita Pillai, Senior Vice President, Culture and DEI and Chief DEI Officer
  • George Poth, Senior Vice President, Real Estate & Facilities Management
  • Alessandra Ravetti, Senior Vice President, Associate General Counsel
  • Kerry Reinertsen, PhD, Senior Vice President, Strategic Alliances
  • David Snow, Senior Vice President, Global Head, Dupixent Franchise
  • Mark Volpe, Senior Vice President, Tax
  • Bola Akinlade, MD, FACP, Senior Vice President, Clinical Development, Immunology and Inflammation
  • Hanne Bak, PhD, Senior Vice President, Preclinical Manufacturing and Process Development
  • Aris Baras, MD, Senior Vice President, Regeneron Genetics Center®
  • Ned Braunstein, MD, Executive Vice President, Regulatory Affairs and Global Patient Safety
  • Gang Chen, PhD, Senior Vice President, Protein Expression Sciences
  • Thomas DiCioccio, PhD, Senior Vice President, Pharmacometrics
  • Benjamin Drosman, Senior Vice President, Global Development Quality & Regulatory Compliance
  • Gregory Geba, MD, PhD, Senior Vice President, Global Development Scientific Council
  • Philip Gregory, DPhil, Senior Vice President, Regeneron Cell Medicines
  • Gary Herman, MD, Senior Vice President, Early Clinical Development and Experimental Sciences
  • Boaz Hirshberg, MD, Senior Vice President, Clinical Sciences General Medicine
  • Diana Hughes, MBBS, Senior Vice President, Global Patient Safety
  • Bari Kowal, Senior Vice President, Development Operations and Portfolio Management
  • Christos Kyratsous, PhD, Senior Vice President, Research
  • Johnathan Lancaster, MD, PhD, Senior Vice President, Global Medical Affairs
  • John Lin, MD, PhD, Senior Vice President, Immuno-Oncology and Head of Bispecifics
  • Israel Lowy, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Oncology
  • Lynn Macdonald, PhD, Senior Vice President, Research
  • Lori Morton, PhD, Senior Vice President, Research
  • Andrew Murphy, PhD, Executive Vice President, Research
  • Muriel O'Byrne, PhD, Senior Vice President, International Regulatory Affairs & Head, European Business Office
  • William Olson, PhD, Senior Vice President, Therapeutic Proteins
  • Mohammed Shameem, PhD, Senior Vice President, Formulations Development
  • L. Andres Sirulnik, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Hematology
  • Randy Soltys, PhD, Senior Vice President, Drug Safety and Pharmacometrics
  • Neil Stahl, PhD, Executive Vice President, Research and Development
  • Robert Vitti, MD, Senior Vice President, Clinical Trial Excellence Strategy
  • Brian Zambrowicz, PhD, Executive Vice President, Functional Genomics and Chief VelociGene® Operations
  • Rajesh Ahuja, Senior Vice President, Fill/Finish and External Manufacturing
  • Frederick Austin, Senior Vice President, Quality Control, Raheen
  • Christine Childrose, Senior Vice President, Human Resources and HR Operations
  • David Crenshaw, Senior Vice President, Associate General Counsel
  • Tikiri Dissanayake, Senior Vice President, IOPS Technical Operations
  • Patrice Gilooly, Senior Vice President, Quality Assurance and Operations
  • Jennifer McNay, PhD, Senior Vice President, CMC Regulatory Sciences and Industrial Affairs
  • Niall O’Leary, Senior Vice President and Site Head, IOPS Raheen
  • Scott Oberman, Senior Vice President, Supply Chain Operations
  • David Simon, Senior Vice President, IOPS Finance and Business Operations
  • Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply
  • Benjamin Yocum, Senior Vice President, Manufacturing Operations
  • James Wolfe, Senior Vice President, Process Sciences and Drug Product Engineering
  • Bonnie L. Bassler, PhD, Director
  • Michael S. Brown, MD, Director
  • N. Anthony Coles, MD, Chair of the Board
  • Joseph L. Goldstein, MD, Director
  • Kathryn Guarini, PhD, Director
  • Christine A. Poon, Lead Independent Director
  • Arthur F. Ryan, Director
  • Huda Y. Zoghbi, MD, Director
  • Samantha Dickon, Director, Development Program Management
  • Gervasio Batista, Sr. Scientist, Neuroscience
  • James K. Gibson, Senior Regional Director, Immunology/Pulmonary
  • Beth Brause, Director, Field Reimbursement Management
  • Eric Prendergast, Director, Pricing Strategy
  • Ashley Neff, Manager, Digital Communications
  • Shari Loock, Associate Director, Sourcing
  • Jennifer Davidson Hamilton, VP and Head of Precision Medicine
  • Yi Zhang, Director, Health Economics & Outcomes Research
  • Wilson Caldwell III, Director, GCO Vendor & Relationship Management
  • David Stein, Director, Medical Operations
  • Regeneron, Corporate
  • Grant Anicete, Biotech Production Specialist I / IOPS Rensselaer
  • Mary McKenna, Lead Quality Control Analyst / IOPS Raheen
  • Ashley Lebby, Lead Senior Biotech Production Specialist / IOPS Rensselaer
  • Varenka Rodriguez Diblasi, Principal Scientist, Bioinformatics
  • Jessie Brown, Manager, Integrative Translational Genetics
  • Gisu Eom, Lead Cloud DevOps Engineer
  • Carmen Kenworthy, Scientist, Velocigene
  • Ralph Hazlewood, Sr. Manager, Research Program Management
  • Brandy Bennett, Sr. Director, R&D Strategy & Operations

Last updated: 2024-12-31

MannKind Corporation

MannKind Corporation logo
Market Cap: High
Employees: Medium

Afrezza

Mann Kind Corporation is a biopharmaceutical company specializing in inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin for diabetes control, and promotes Thyquidity for hypothyroidism treatment.

Tags: biopharmaceutical, diabetes, endocrine diseases, hypothyroidism, inhaled insulin, therapeutic products

Symbol: MNKD

Recent Price: $6.52

Industry: Biotechnology

CEO: Dr. Michael E. Castagna Pharm.D.

Sector: Healthcare

Employees: 411

Address: 30930 Russell Ranch Road, Westlake Village, CA 91362

Phone: 818 661 5000

Last updated: 2024-12-31

Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

REN001

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing therapies for patients with rare genetic mitochondrial diseases. Its primary product, REN001, is a selective peroxisome proliferator-activated receptor delta agonist currently in clinical trials.

Tags: Clinical Trials, Genetic Disorders, Mitochondrial Diseases, Pharmaceuticals, Therapeutics

Symbol: RPHM

Recent Price: $18.20

Industry: Biotechnology

CEO: Mr. Gregory J. Flesher

Sector: Healthcare

Employees: 8

Address: 18575 Jamboree Road, Irvine, CA 92612

Phone: 619 733 3852

Last updated: 2024-12-31

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. logo
Market Cap: Highest
Employees: Medium

EXONDYS 51, VYONDYS 53, AMONDYS 45, SRP-5051, SRP-9001, SRP-9003

Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA-targeted therapeutics and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy.

Tags: Duchenne muscular dystrophy, RNA-targeted therapeutics, biopharmaceutical, gene therapy, rare diseases

Symbol: SRPT

Recent Price: $121.19

Industry: Biotechnology

CEO: Mr. Douglas S. Ingram Esq.

Sector: Healthcare

Employees: 1314

Address: 215 First Street, Cambridge, MA 02142

Phone: 617 274 4000

Leadership

  • Douglas S. Ingram, President and Chief Executive Officer
  • Bilal Arif, Executive Vice President, Chief Technical Operations Officer
  • Diane Berry, PhD, Executive Vice President, Chief Global Policy & Advocacy Officer
  • Ryan E. Brown, JD, Executive Vice President, Chief General Counsel
  • Ian M. Estepan, Executive Vice President, Chief Financial Officer
  • Dallan Murray, Executive Vice President, Chief Customer Officer
  • Alison Nasisi, Executive Vice President, Chief People Officer
  • Louise R. Rodino-Klapac, PhD, Executive Vice President, Head of R&D, Chief Scientific Officer
  • Will Tilton, Senior Vice President, Head of Strategy, Chief of Staff
  • M. Kathleen Behrens, PhD, Chairwoman
  • Richard J. Barry,
  • Kathryn Boor, PhD,
  • Michael Chambers,
  • Deirdre Connelly,
  • Stephen L. Mayo, PhD,
  • Claude Nicaise, MD,
  • Hans Wigzell, MD, PhD,
  • John C. Martin, PhD (In Memoriam),
  • Annemieke Aartsma-Rus, PhD,
  • Carsten Bönnemann, MD,
  • Joy Cavagnaro, PhD, DABT, Fellow ATS,
  • Kay Davies, PhD, DBE FMedSci FRS,
  • Steven Gray, PhD,
  • Angela J. Russell, DPhil,

Last updated: 2024-12-31

Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc. logo
Market Cap: Medium
Employees: Lowest

TSHA-120, TSHA-102, TSHA-121, TSHA-118, TSHA-105, TSHA-101

Taysha Gene Therapies, Inc. focuses on developing adeno-associated virus-based gene therapies for treating monogenic diseases of the central nervous system, with a pipeline including treatments for conditions such as giant axonal neuropathy, Rett syndrome, and GM2 gangliosidosis.

Tags: CNS, biotechnology, gene therapy, healthcare, monogenic diseases

Symbol: TSHA

Recent Price: $1.73

Industry: Biotechnology

CEO: Mr. Sean P. Nolan

Sector: Healthcare

Employees: 52

Address: 3000 Pegasus Park Drive, Dallas, TX 75247

Phone: 214 612 0000

Last updated: 2024-12-31

Agenus Inc.

Agenus Inc. logo
Market Cap: Low
Employees: Medium

Retrocyte Display

Agenus Inc. is a clinical-stage immuno-oncology company that discovers and develops immuno-oncology products, offering antibody expression platforms, vaccine programs, and various monoclonal antibodies for cancer treatment.

Tags: antibody expression, cancer treatment, clinical trials, immuno-oncology, vaccine development

Symbol: AGEN

Recent Price: $2.69

Industry: Biotechnology

CEO: Dr. Garo H. Armen Ph.D.

Sector: Healthcare

Employees: 389

Address: 3 Forbes Road, Lexington, MA 02421-7305

Phone: 781 674 4400

Last updated: 2024-12-31

Erasca, Inc.

Erasca, Inc. logo
Market Cap: Medium
Employees: Low

ERAS-007, ERAS-601, ERAS-801

Erasca, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

Tags: ERAS-007, ERAS-601, ERAS-801, RAS/MAPK, biopharmaceutical, cancers

Symbol: ERAS

Recent Price: $2.55

Industry: Biotechnology

CEO: Dr. Jonathan E. Lim M.D.

Sector: Healthcare

Employees: 126

Address: 10835 Road to the Cure, San Diego, CA 92121

Phone: 858 465 6511

Last updated: 2024-12-31

Generation Bio Co.

Generation Bio Co. logo
Market Cap: Low
Employees: Low

genetic medicines

Generation Bio Co. is a genetic medicines company developing therapies for rare and prevalent diseases, with a focus on the liver, retina, skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and is headquartered in Cambridge, Massachusetts.

Tags: CNS, genetic medicines, liver, oncology, prevalent diseases, rare diseases, retina, skeletal muscle

Symbol: GBIO

Recent Price: $1.06

Industry: Biotechnology

CEO: Dr. Cameron Geoffrey McDonough M.D.

Sector: Healthcare

Employees: 174

Address: 301 Binney Street, Cambridge, MA 02142

Phone: 617 655 7500

Last updated: 2024-12-31

Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. logo
Market Cap: Low
Employees: Lowest

GP2

Greenwich Life Sciences, Inc. is a clinical stage biopharmaceutical company focusing on developing novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers, with a lead product candidate GP2, which aims to prevent breast cancer recurrences.

Tags: GP2, HER2/neu, biopharmaceutical, breast cancer, cancer immunotherapy, clinical trial

Symbol: GLSI

Recent Price: $10.91

Industry: Biotechnology

CEO: Mr. Snehal S. Patel

Sector: Healthcare

Employees: 3

Address: Building 14, Stafford, TX 77477

Phone: 832 819 3232

Last updated: 2024-12-31

Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock logo
Market Cap: Low
Employees: Low

LX2006, LX2020, LX2021, LX2022, LX1001, LX1020, LX1021, LX1004

Lexeo Therapeutics is a clinical-stage genetic medicine company developing innovative gene therapy candidates targeting hereditary and acquired diseases, including cardiomyopathies and neurological conditions.

Tags: APOE4, Batten disease, acquired diseases, cardiomyopathy, gene therapy, genetic medicine, hereditary diseases

Symbol: LXEO

Recent Price: $6.54

Industry: Biotechnology

CEO: Mr. R. Nolan Townsend

Sector: Healthcare

Employees: 69

Address: 345 Park Avenue South, New York, null 10010

Phone: 212-547-9879

Last updated: 2024-12-31

Neurogene Inc.

Neurogene Inc. logo
Market Cap: Medium
Employees: Low

NGN-401, NGN-101

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases, focusing on gene therapy products like NGN-401 for Rett syndrome and NGN-101 for neuronal ceroid lipofuscinosis subtype 5 batten disease.

Tags: Rett syndrome, biotechnology, gene therapy, genetic medicines, life sciences, neurological diseases, neuronal ceroid lipofuscinosis

Symbol: NGNE

Recent Price: $22.28

Industry: Biotechnology

CEO: Dr. Rachel L. McMinn Ph.D.

Sector: Healthcare

Employees: 91

Address: 535 W 24th Street, New York, NY 10011

Phone: (877) 237-5020

Last updated: 2024-12-31

Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Low

Gene Therapies

Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with multiple clinical-stage programs targeting disorders such as fanconi anemia, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, and Danon disease.

Tags: Biotechnology, Clinical Stage, Gene Therapy, Healthcare, Rare Diseases

Symbol: RCKT

Recent Price: $12.03

Industry: Biotechnology

CEO: Dr. Gaurav D. Shah M.D.

Sector: Healthcare

Employees: 268

Address: 9 Cedarbrook Drive, Cranbury, NJ 08512

Phone: 609 659 8001

Last updated: 2024-12-31

Regulus Therapeutics Inc.

Regulus Therapeutics Inc. logo
Market Cap: Low
Employees: Lowest

RG-012 and RGLS8429

Regulus Therapeutics Inc., based in San Diego, focuses on discovering and developing drugs targeting micro RNAs for treating various diseases.

Tags: biopharmaceutical, clinical stage, drug development, kidney disease, micro RNAs

Symbol: RGLS

Recent Price: $1.50

Industry: Biotechnology

CEO: Mr. Joseph P. Hagan M.B.A.

Sector: Healthcare

Employees: 30

Address: 4224 Campus Point Court, San Diego, CA 92121

Phone: 858 202 6300

Last updated: 2024-12-31

RenovoRx, Inc.

RenovoRx, Inc. logo
Market Cap: Lowest
Employees: Lowest

Renovo Gem

Renovo Rx, Inc. is a clinical-stage biopharmaceutical company focusing on developing therapies for the treatment of solid tumors, with its lead product candidate, Renovo Gem, in Phase III clinical trials for locally advanced pancreatic cancer.

Tags: Renovo Gem, biopharmaceutical, clinical trials, pancreatic cancer, solid tumors

Symbol: RNXT

Recent Price: $1.39

Industry: Biotechnology

CEO: Mr. Shaun R. Bagai

Sector: Healthcare

Employees: 8

Address: 4546 El Camino Real, Los Altos, CA 94022

Phone: 650 284 4433

Leadership

  • Shaun R. Bagai, Director and Chief Executive Officer
  • Ramtin Agah, MD, Chairman, Chief Medical Officer, and Founder
  • Leesa Gentry, Chief Clinical Officer
  • Ronald B. Kocak, CPA, VP Controller and Principal Accounting Officer
  • Ryan Witt, Senior Vice President, Head of Corporate Strategy and Partnerships
  • Imtiaz Qureshi, MD, Director of Imaging
  • Angela Macfarlane, CEO of Perceive Biotherapeutics, Inc.
  • Laurence J. Marton, MD, Director
  • Una S. Ryan, PhD, OBE, Director
  • Robert J. Spiegel, Director

Last updated: 2024-12-31

MeiraGTx Holdings plc

MeiraGTx Holdings plc logo
Market Cap: Low
Employees: Medium

Gene Therapy Treatments

Meira GTx Holdings plc is a clinical stage gene therapy company developing treatments for serious diseases, including ocular diseases, xerostomia, and neurodegenerative conditions. They are in various stages of clinical development for several gene therapy programs and have a research collaboration with Janssen Pharmaceuticals.

Tags: Clinical Stage, Gene Therapy, Neurodegenerative Diseases, Ocular Diseases, Research Collaboration, Xerostomia

Symbol: MGTX

Recent Price: $5.89

Industry: Biotechnology

CEO: Dr. Alexandria Forbes Ph.D.

Sector: Healthcare

Employees: 387

Address: 430 East 29th Street, New York, NY 10016

Phone: 646 860 7985

Leadership

  • Alexandria Forbes, Ph.D., Board Member, President and Chief Executive Officer
  • Richard Giroux, Chief Operating Officer and Chief Financial Officer
  • Stuart Naylor, Ph.D., Chief Development Officer
  • Robert K. Zeldin, M.D., Chief Medical Officer
  • Robert Wollin, JD, General Counsel and Secretary
  • Alastair Leighton, Ph.D, SVP, Manufacturing and Supply Chain
  • Christine Sheehy, SVP, Global Integration
  • Tim Randall, SVP, Risk and Internal Controls
  • Michel Michaelides, M.D., Head of Clinical Ophthalmology
  • Tassos Georgiadis, Ph.D., Vice President, Preclinical Development
  • Keith R. Harris, Ph.D., Chairman of the Board
  • Ellen Hukkelhoven, Ph.D., Board Member
  • Lord Mendoza, Independent Board Member
  • Nicole Seligman, Independent Board Member
  • Thomas E. Shenk, Ph.D., Independent Board Member
  • Debra Yu, M.D., Independent Board Member

Last updated: 2024-12-31

Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. logo
Market Cap: Low
Employees: Lowest

NXP800, NXP900

Nuvectis Pharma, Inc., is a biopharmaceutical company that focuses on developing precision medicines for treating serious unmet medical needs in oncology. It is working on products like NXP800, a heat shock factor 1 pathway inhibitor, and NXP900, a drug candidate targeting Proto-oncogene c-Src and YES1 kinases.

Tags: NXP800, NXP900, biopharmaceutical, oncology, precision medicine

Symbol: NVCT

Recent Price: $5.14

Industry: Biotechnology

CEO: Mr. Ron Bentsur M.B.A.

Sector: Healthcare

Employees: 13

Address: 1 Bridge Plaza, Fort Lee, NJ 07024

Phone: 201 614 3150

Last updated: 2024-12-31

Orgenesis Inc.

Orgenesis Inc. logo
Market Cap: Lowest
Employees: Low

Point of Care (POCare) platform

Orgenesis Inc. is a biotech company focusing on cell and gene therapies. It offers a Point of Care (POCare) platform with a pipeline of POCare therapeutics produced in automated systems, targeting autologous therapies near the patient's point of care.

Tags: POCare, autologous therapies, biotech, cell therapy, gene therapy

Symbol: ORGS

Recent Price: $2.11

Industry: Biotechnology

CEO: Ms. Vered Caplan M.Sc.

Sector: Healthcare

Employees: 146

Address: 20271 Goldenrod Lane, Germantown, MD 20876

Phone: 480 659 6404

Last updated: 2024-12-31